TheraRadar
← Back
Data updated: Jul 17, 2026

INNOCOLL PHARMS

Pharma
GastroenterologyInfectious Disease Execution: Excellent

INNOCOLL PHARMS is a pharmaceutical company focused on Gastroenterology, Infectious Disease. Key products include XARACOLL.

2020
Since
1
Drugs
-
Trials
0
New Drugs (2yr)

INNOCOLL PHARMS at a Glance

  • Strong track record with 91% execution quality across 16 trials
  • Fast trial execution (8 months median completion)

INNOCOLL PHARMS's Key Drugs

INNOCOLL PHARMS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

INNOCOLL PHARMS's Recent FDA Approvals

New NDA/BLA approvals for INNOCOLL PHARMS over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

INNOCOLL PHARMS's Therapeutic Areas

INNOCOLL PHARMS's approved drugs and pipeline span 2 therapeutic areas, led by Gastroenterology and Infectious Disease. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Gastroenterology 50%
0 drugs Phase 3: 2 Phase 2: 2
Infectious Disease 50%
0 drugs Phase 3: 3

INNOCOLL PHARMS's Top Competitors

INNOCOLL PHARMS's closest competitors by therapeutic-area and drug-target overlap include Johnson & Johnson, Bristol-Myers Squibb, and APOTHECON. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Johnson & Johnson big-pharma
Infectious Disease, Gastroenterology
Bristol-Myers Squibb big-pharma
Infectious Disease, Gastroenterology
APOTHECON specialty
Infectious Disease, Gastroenterology
PF PRISM CV big-pharma
Infectious Disease, Gastroenterology
ASTELLAS specialty
Gastroenterology, Infectious Disease

INNOCOLL PHARMS Pipeline Snapshot

INNOCOLL PHARMS has 7 active clinical programs from ClinicalTrials.gov — 5 Phase 3, 2 Phase 2 and 0 Phase 1.

5
Phase 3
2
Phase 2
0
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Gastroenterology pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 7/7 completed
  • • Speed: 8 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges